<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02162888</url>
  </required_header>
  <id_info>
    <org_study_id>EGL-BDM-C-1301</org_study_id>
    <nct_id>NCT02162888</nct_id>
  </id_info>
  <brief_title>A Phase I, Bioequivalence Study to Evaluate Two Formulations of Bendamustine (BDM) Hydrochloride (HCl) Administered to Cancer Patients</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eagle Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eagle Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to demonstrate that a new formulation of an Bendamustine (BDM)
      Hydrochloride (HCl) is bioequivalent (BE) (similar) to the commercially available product in
      patients with cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open-label, randomized, crossover, Phase I study intended to demonstrate the BE,
      and safety and tolerability profile of 2 formulations of BDM HCl administered to cancer
      patients: Eagle-BDM and Teva-BDM Histologically confirmed diagnosis of any malignant disease
      (solid tumors and hematologic malignancies are eligible) for which no curative or standard
      therapy is appropriate.

      At the end of the study, patients may be enrolled into an open-label extension (OLE) study
      (Study EGL-BDM-C-1301-OLE), at the discretion of the investigator.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2013</start_date>
  <completion_date type="Actual">November 2014</completion_date>
  <primary_completion_date type="Actual">November 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To demonstrate bioequivalent area under the time concentration curve (AUC) for both drug products</measure>
    <time_frame>Participants will be in the study for up to 65 days</time_frame>
    <description>Each patient will receive 3, single doses of study medication in a 56 day treatment period (2 cycles of 28 days each). Medication will be administered on Cycle 1, Day 1; Cycle 1, Day 2; and Cycle 2, Day 1. Each patient will receive 1 dose of Eagle-BDM and 2 doses of Teva-BDM in 3 randomly assigned, varying treatment sequences(Eagle-BDM, Teva-BDM, Teva-BDM; Teva-BDM, Eagle-BDM, Teva-BDM; or Teva-BDM, Teva-BDM, Eagle-BDM). Pharmacokinetic assessments will be performed.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">81</enrollment>
  <condition>Cancer Which Has Either Progressed or Relapsed After Standard Therapy, or for Which no Curative or Standard Therapy is Appropriate</condition>
  <arm_group>
    <arm_group_label>Eagle-BDM; Teva-BDM; Teva-BDM</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Eagle-BDM: IV Teva-BDM: IV</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Teva-BDM; Eagle-BDM;Teva-BDM</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Eagle-BDM: IV Teva-BDM: IV</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Teva-BDM, Teva-BDM, Eagle-BDM</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Eagle-BDM: IV Teva-BDM: IV</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Test Product (Bendamustine)</intervention_name>
    <arm_group_label>Eagle-BDM; Teva-BDM; Teva-BDM</arm_group_label>
    <arm_group_label>Teva-BDM; Eagle-BDM;Teva-BDM</arm_group_label>
    <arm_group_label>Teva-BDM, Teva-BDM, Eagle-BDM</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically confirmed diagnosis of any malignant disease for which no curative or
             standard therapy is appropriate.

          -  Bone Marrow Function and Blood Chemistry results within protocol limits

        Exclusion Criteria:

          -  CLL

          -  HIV

          -  Presence of brain metastases
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Oncology Institute of Hope and Innovation</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Center of Kansas</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regional Cancer Care Associates</name>
      <address>
        <city>Cherry Hill</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Penn State University Hershey Medical Center</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Greenville Hospital System University Medical Center</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Oncology</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Scott &amp; White Healthcare</name>
      <address>
        <city>Temple</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virginia Oncology Associates</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Evergreen Hematology &amp; Oncology</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yakima Valley Memorial Hospital/North Star Lodge</name>
      <address>
        <city>Yakima</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 4, 2014</study_first_submitted>
  <study_first_submitted_qc>June 10, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 13, 2014</study_first_posted>
  <last_update_submitted>November 5, 2014</last_update_submitted>
  <last_update_submitted_qc>November 5, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 6, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bendamustine Hydrochloride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

